Abstract:AIM To evaluate the effects of duloxetine on cognitive function and neuroendocrine status after 12 weeks of therapy in patients with depression.METHODS Twenty-seven patients(10 men,17 women) with depression were treated by duloxetine(flexible dose ranging from 60 mg to 120 mg) for 12 weeks.Fasting venous blood samples were obtained for determinating serum thyroid stimulating hormone(TSH),total triiodothyronine(TT3),free triiodothyronine(FT3),total thyroxine(TT4),free thyroxine(FT4),corticotrophin (ACTH) and Cortisol concentrations,both at baseline and after 12 weeks of therapy.These patients were evaluated by Wisconsin Card Sorting Test(WCST),Trail Making Test(TMT),Verbal Fluency Test(VFT), Digit Span and Digit Symbol of Wechsler Adult Intelligence Scale Revised Chinese(WAIS-RC) and Tower of Hanoi(TOH) before or after the treatment with duloxetine.The Hamilton Depression Scale 17-item(HAMD- 17) total score and factors scores were rated before and 1,2,4,8,12 weeks after the treatment with duloxetine.RESULTS The scores of Digit Span(14.35±3.21) and Digit Symbol(49.50±15.36) of WAISRC after the treatment were significantly higher than those before treatment(13.50±3.15,46.50±14.91),P0.05,with no significant changes in WCST,TMT,VFT and TOH(P0.05).A significant decrease in FT4 concentrations was found between baseline(13.59±4.55 pmol·L~(-1)) and the end of the treatment(11.89±4.02 pmol·L~(-1)),P0.05,with no significant changes found in FT3,TT3,TT4,TSH,ACTH and Cortisol levels (P0.05).In addition,there was a significant negative correlation between the change of TT4(correlative coefficient= -0.513,P = 0.029) or FT3(correlative coefficient = - 0.420,P = 0.036) levels and the decrease rate(%) in the HAMD-17 scores.There was no significant correlation between other HPT axis levels and the decrease rate in the HAMD-17 scores.The decrease rate in the HAMD-17 scores was significantly positive correlated with the TOH total time(correlative coefficient = 0.441,P = 0.027).No statistically significant relationships were found between other cognition and the decrease rate in the HAMD-17 scores.After the treatment,the total effective rate was 78%(21/27) and the recovery rate was 56%(15/27).CONCLUSION A twelve-week treatment with duloxetine may treat paitents effectively and improve their memory and cognitive functions,which may be associated with the effect on hypothalamic-pituitary-thyroid axis.

Effect of Duloxetine on Cognitive Function and Neuroendocrine in Patients with Depression

Effects of Antidepressant Treatment on Cognitive Control Network in Patients with Major Depressive Disorder

[Repetitive Transcranial Magnetic Stimulation Combined with Antidepressant Medication in Treatment of First-Episode Patients with Major Depression].

Comparison of the Effectiveness of Duloxetine in Depressed Patients with and Without a Family History of Affective Disorders in First-Degree Relatives.

An Analysis on the Cognitive Function in Depression Before and after Therapy

Duloxetine Effects on Striatal Resting-State Functional Connectivity in Patients with Major Depressive Disorder.

The effectiveness of vortioxetine on neurobiochemical metabolites and cognitive of major depressive disorders patients: A 8-week follow-up study

Study on the curative effect of the Cognitive-behavioral therapy combined with Duloxetine in the treatment of depression with somatic disorder

Repetitive Transcranial Magnetic Stimulation In Combination With Citalopram In Young Patients With First-Episode Major Depressive Disorder: A Double-Blind, Randomized, Sham-Controlled Trial

An Initial Exploration of Hair Cortisol Responses to Antidepressants in Unmedicated Patients with Depression

Striatal Functional Connectivity Alterations after Two-Week Antidepressant Treatment Associated to Enduring Clinical Improvement in Major Depressive Disorder

Functional connectivity between the habenula and posterior default mode network contributes to the response of the duloxetine effect in major depressive disorder

The efficacy and tolerability of duloxetine in the treatment of anxious versus non-anxious depression: a post-hoc analysis of an open-label outpatient study

Distinct functional networks associated with improvement of affective symptoms and cognitive function during citalopram treatment in geriatric depression

Research on Cognitive Function in Anxious Depression Patients in China

The Effectiveness and Safety Analysis of Duloxetine in Treating Comorbid Depression in Parkinson's Disease: A Retrospective Study

A comparison of efficacy on alexithymia between escitalopram and duloxetine in patients with major depressive disorder

Effect of transcranial magnetic stimulation in combination with citalopram on patients with post-stroke depression

Multi-center,randomized,and double-blind controlled clinical trial of duloxetine enteric capsule in treatment of depression

Effect of Treatment with Citalopram on Curative Effect of Coronary Heart Disease Patients with Depression

Duloxetine Enteric-coated Tablets Versus Paroxetine in the Treatment of Major Depressive Disorder: A Double-blind, Double-dummy, Randomized Controlled Clinical Trial